Serveur d'exploration Tocilizumab - Analysis (France)

Index « Auteurs » - entrée « Philip G. Conaghan »
Attention, ce site est en cours de développement !
Attention, site généré par des moyens informatiques à partir de corpus bruts.
Les informations ne sont donc pas validées.
Philip Conaghan < Philip G. Conaghan < Philip Hawkins  Facettes :

List of bibliographic references

Number of relevant bibliographic references: 5.
Ident.Authors (with country if any)Title
000310 (2016) Charles Peterfy [États-Unis] ; Gerd R. Burmester [Allemagne] ; Vivian P. Bykerk [États-Unis] ; Bernard G. Combe [France] ; Julie C. Dicarlo [États-Unis] ; Daniel E. Furst [États-Unis] ; Tom W J. Huizinga ; Dennis A. Wong [États-Unis] ; Philip G. Conaghan [Royaume-Uni] ; Paul Emery [Royaume-Uni]Sustained improvements in MRI outcomes with abatacept following the withdrawal of all treatments in patients with early, progressive rheumatoid arthritis
000461 (2014) Maxime Dougados [France] ; Karsten Kissel [Australie] ; Philip G. Conaghan [Royaume-Uni] ; Emilio Martin Mola [Espagne] ; Georg Schett [Allemagne] ; Roberto Gerli [Italie] ; Michael Sejer Hansen [Danemark] ; Howard Amital [Israël] ; Ricardo M. Xavier [Brésil] ; Orrin Troum [États-Unis] ; Corrado Bernasconi [Suisse] ; T W J. Huizinga [Pays-Bas]Clinical, radiographic and immunogenic effects after 1 year of tocilizumab-based treatment strategies in rheumatoid arthritis: the ACT-RAY study
000462 (2014) T W J. Huizinga [Pays-Bas] ; Philip G. Conaghan [Royaume-Uni] ; Emilio Martin-Mola [Espagne] ; Georg Schett [Allemagne] ; Howard Amital [Israël] ; Ricardo M. Xavier [Brésil] ; Orrin Troum [États-Unis] ; Maher Aassi ; Corrado Bernasconi ; Maxime Dougados [France]Clinical and radiographic outcomes at 2 years and the effect of tocilizumab discontinuation following sustained remission in the second and third year of the ACT-RAY study
000517 (2013) Philip G. Conaghan [Royaume-Uni] ; Patrick Durez [Belgique] ; Rieke E. Alten [Allemagne] ; Gerd-Rüdiger Burmester [Allemagne] ; Paul P. Tak [Pays-Bas, Royaume-Uni] ; Lars Klareskog [Suède] ; Anca Irinel Catrina [Suède] ; Julie Dicarlo [États-Unis] ; Corine Gaillez [France] ; Manuela Le Bars [France] ; Xianhuang Zhou [États-Unis] ; Charles Peterfy [États-Unis]Impact of intravenous abatacept on synovitis, osteitis and structural damage in patients with rheumatoid arthritis and an inadequate response to methotrexate: the ASSET randomised controlled trial
000520 (2013) Maxime Dougados [France] ; Karsten Kissel [Suisse] ; Tom Sheeran [Royaume-Uni] ; Paul P. Tak [Pays-Bas] ; Philip G. Conaghan [Royaume-Uni] ; Emilio Martín Mola [Espagne] ; Georg Schett [Allemagne] ; Howard Amital [Israël] ; Federico Navarro-Sarabia [Espagne] ; Antony Hou [États-Unis] ; Corrado Bernasconi [Suisse] ; Twj Huizinga [Pays-Bas]Adding tocilizumab or switching to tocilizumab monotherapy in methotrexate inadequate responders: 24-week symptomatic and structural results of a 2-year randomised controlled strategy trial in rheumatoid arthritis (ACT-RAY)

List of associated KwdEn.i

Nombre de
documents
Descripteur
3Arthritis, Rheumatoid (diagnostic imaging)
3Arthritis, Rheumatoid (drug therapy)
3Double-Blind Method
3Female
3Humans
3Middle Aged
3Radiography
2Aged
2Antibodies, Monoclonal, Humanized (therapeutic use)
2Antirheumatic Agents (therapeutic use)
2Blood Sedimentation
2Disease Progression
2Male
2Methotrexate (therapeutic use)
2Treatment Outcome
1Adult
1Antibodies, Monoclonal, Humanized (administration & dosage)
1Antibodies, Monoclonal, Humanized (adverse effects)
1Antibodies, Monoclonal, Humanized (immunology)
1Antibodies, Neutralizing (blood)
1Antibody Formation (drug effects)
1Antineoplastic agent
1Antirheumatic Agents (administration & dosage)
1Antirheumatic Agents (adverse effects)
1Antirheumatic Agents (immunology)
1Antirheumatic agent
1Arthritis, Rheumatoid (blood)
1Arthritis, Rheumatoid (pathology)
1Chronic
1Drug Therapy, Combination
1Foot Joints (diagnostic imaging)
1Hand Joints (diagnostic imaging)
1Immunomodulator
1Immunosuppressive agent
1Induction Chemotherapy
1Longitudinal Studies
1Maintenance Chemotherapy
1Methotrexate
1Methotrexate (administration & dosage)
1Methotrexate (adverse effects)
1Rheumatoid arthritis
1Rheumatology
1Symptomatology
1Tocilizumab

Pour manipuler ce document sous Unix (Dilib)

EXPLOR_STEP=$WICRI_ROOT/Sante/explor/TocilizumabV1/Data/France/Analysis
HfdIndexSelect -h $EXPLOR_AREA/Data/France/Analysis/Author.i -k "Philip G. Conaghan" 
HfdIndexSelect -h $EXPLOR_AREA/Data/France/Analysis/Author.i  \
                -Sk "Philip G. Conaghan" \
         | HfdSelect -Kh $EXPLOR_AREA/Data/France/Analysis/biblio.hfd 

Pour mettre un lien sur cette page dans le réseau Wicri

{{Explor lien
   |wiki=    Sante
   |area=    TocilizumabV1
   |flux=    France
   |étape=   Analysis
   |type=    indexItem
   |index=    Author.i
   |clé=    Philip G. Conaghan
}}

Wicri

This area was generated with Dilib version V0.6.34.
Data generation: Fri May 22 09:34:00 2020. Site generation: Sun Mar 28 09:01:19 2021